Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Manming Cao"'
Autor:
Qiong Lyu, Weiliang Zhu, Ting Wei, Weimin Ding, Manming Cao, Qiongyao Wang, Linlang Guo, Peng Luo, Jian Zhang
Publikováno v:
Cancer Medicine, Vol 10, Iss 21, Pp 7863-7876 (2021)
Abstract Background The majority of patients with small‐cell lung cancer (SCLC) show a good response in the early stages of treatment, but more than 90% of patients will develop drug resistance. Therefore, biomarkers are urgently needed to identify
Externí odkaz:
https://doaj.org/article/f6cf9ddb76a74f719ffcb00033813430
Publikováno v:
Cancer Cell International, Vol 21, Iss 1, Pp 1-14 (2021)
Abstract Background Gastric cancer (GC) is a common malignancy of the digestive system. Antioxidant activity is regarded as a possible mechanism in ectopic cancer. Hence, oxidative stress regulation is being evaluated for cancer treatment. Previous r
Externí odkaz:
https://doaj.org/article/4516a33d7dd04d878f46bccfadbbf06f
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Objective: Resistance to immune checkpoint inhibitors (ICIs) has been a massive obstacle to ICI treatment in metastatic urothelial carcinoma (MUC). Recently, increasing evidence indicates the clinical importance of the association between hypoxia and
Externí odkaz:
https://doaj.org/article/03debf4e76a9449d86dfbfc4f9da5528
Autor:
Yueming Zhang, Xuechun Li, Rui Zhou, Anqi Lin, Manming Cao, Qingwen Lyu, Peng Luo, Jian Zhang
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Urothelial cancer (UC) is one of the common refractory tumors and chemotherapy is the primary treatment for it. The advent of immune checkpoint inhibitors (ICI) has facilitated the development of treatment strategies for UC patients. To screen out UC
Externí odkaz:
https://doaj.org/article/ca8e576406b2498a84689ae356c14a38
Autor:
Chaozheng Zhou, Anqi Lin, Manming Cao, Weimin Ding, Weiming Mou, Ningyi Guo, Zhenyu Chen, Jian Zhang, Peng Luo
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Immune checkpoint inhibitors (ICIs) have changed the treatment paradigm of metastatic urothelial carcinoma (mUC), a dominant type of bladder cancer (BC). Previous studies have shown an association between gene mutations in the DNA damage response (DD
Externí odkaz:
https://doaj.org/article/272500c79d814bc7aa797be92a69376f
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Age is a potential predictive marker for the prognosis of cancer patients treated with immune checkpoint inhibitors (ICIs), but the appropriate age cutoff point is still controversial. We aimed to explore the influence of different age cutoff points
Externí odkaz:
https://doaj.org/article/f7b5ece4f1dd4a3fbb065083366bc0ed
Publikováno v:
Cancer Control, Vol 27 (2020)
In recent years, immune checkpoint inhibitors (ICIs) targeting CTLA-4 or PD1/PDL1 have achieved remarkable success in the treatment of bladder cancer (BLCA), but only a few patients have shown durable clinical benefits. The prognostic role of a mutan
Externí odkaz:
https://doaj.org/article/ed277d9f97df48e2b1246b4fe0166fe5
Publikováno v:
Frontiers in Genetics, Vol 11 (2020)
Immune checkpoint inhibitors (ICIs) have shown promising results in bladder cancer (BC). However, only some patients respond to ICIs. DNA repair defects (DDR) play an important role in the therapeutic response of bladder cancer. Therefore, we aimed t
Externí odkaz:
https://doaj.org/article/bb0cd37a7ab94749b6f9c4df0dc4e949
Autor:
Peng, Xu, Chunxiao, Chen, Binshen, Chen, Enguang, Bi, Wei, Du, Ning, Jiang, Zhe, Liu, Hekui, Lan, Manming, Cao, Yazhen, Liu, Jingwen, Huang, Haiyan, Shen, Cunrong, Liu, Chunxiao, Liu, Abai, Xu
Publikováno v:
European Urology. 82:543-550
Rhabdomyosarcoma (RMS) is the most common paediatric soft-tissue sarcoma. Approximately 15-20% of RMS cases arise from the bladder and prostate (B/P). The optimal treatment strategy for B/P RMS remains unclear.To retrospectively evaluate the applicab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08a7a41cd45c1645becc5cac97adae4e
https://doi.org/10.1016/j.eururo.2022.08.015
https://doi.org/10.1016/j.eururo.2022.08.015
Autor:
Meiting Chen, Kai Yao, Manming Cao, Hao Liu, Cong Xue, Tao Qin, Lingru Meng, Zhousan Zheng, Zike Qin, Fangjian Zhou, Zhuowei Liu, Yanxia Shi, Xin An
Publikováno v:
Cancer Immunology, Immunotherapy.
Background Phase II trials showed the efficacy of anti-HER2 RC48-ADC (disitamab vedotin) for HER2-positive metastatic urothelial carcinoma (UC). This study evaluated RC48 alone verses in combination with immunotherapy for locally advanced or metastat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d26509d99676cc78d5f708004f1db353
https://doi.org/10.1007/s00262-023-03419-1
https://doi.org/10.1007/s00262-023-03419-1